Return to homepagePandemic Pact

ADJUVANT COMPARISON AND CHARACTERIZATION

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93022C00052-P00004-9999-1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2027

  • Known Financial Commitments (USD)

    $3,018,059

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    BALI PULENDRAN

  • Research Location

    United States of America

  • Lead Research Institution

    STANFORD UNIVERSITY

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles ("immune fingerprints") of adjuvants that work through different mechanisms in the context of SARS-CoV-2 (COVID-19) vaccines.